This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
General Inclusion Criteria (All Participants):
Inclusion Criteria Specific to Arms A and C (R/R MM)
Inclusion Criteria Specific to Arms B and D (R/R NHL)
General Exclusion Criteria (All Participants)
Exclusion Criteria Specific to Arms A and C (R/R MM)
Exclusion Criteria Specific to Arms B and D (R/R NHL)
Other protocol defined inclusion/exclusion criteria could apply
The following is a listing of trial locations that are open and accepting patients.
Deer Park, OH
Deer Park, OH
There are no resources, links or videos to display for this clinical trial.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message